Agilent Certifies BGI as Provider for SureSelect XT Target Enrichment System | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today announced BGI has become a certified service provider for Agilent's SureSelect XT Target Enrichment System for next-generation sequencing.

Based in Shenzhen, China, BGI becomes the first SureSelect XT CSF in that country, and is certified for all SureSelect XT target enrichment protocols, including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA, and custom kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.